Moffitt Cancer Center will present results of the phase 3 NETTER-1 study, showing clinically meaningful and significant results for Lutathera (77 Lu-DOTA 0-Tyr 3-Octreotate) in patients with ...
Lutathera showed antitumor activity in metastatic BP-NETs, with partial responses in 17% of patients and stable disease in 30%. The study reported a median progression-free survival of 10.8 months and ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results